Organogenesis Holdings Inc. $ORGO

What the company doesAI summary of filing

Organogenesis is a regenerative medicine company that develops, manufactures, and sells products for advanced wound care and surgical and sports medicine markets. The company generates revenue from selling wound care products such as Apligraf, Dermagraft, PuraPly, and placental allografts to hospitals, wound care centers, surgery centers, and physician offices, primarily in the United States. It is a revenue-generating company with an expanding pipeline including ReNu, a cryopreserved amniotic suspension for knee osteoarthritis that has completed Phase 3 trials and initiated rolling biologics license application submission. Recent regulatory changes from Medicare, including new payment rates and prior authorization programs effective in 2026, have created significant uncertainty affecting the company's current revenue trajectory. [10-K 2026-02-26]

Segments: Advanced Wound Care (Apligraf, Dermagraft, PuraPly, CYGNUS, Affinity, Novachor, NuShield, SimpliMax), Surgical & Sports Medicine (NuShield, CYGNUS Matrix, PuraForce, Affinity, Novachor, PuraPly variants), Pipeline Products (ReNu, FortiShield, TransCyte, PuraPly extensions, Apligraf/Dermagraft extensions, Placental portfolio expansion)